The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan—Biomarker analysis.
 
Yasushi Tsuji
Honoraria - Bayer; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly Japan; Medicon; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Kohei Shitara
Honoraria - Abbvie; Novartis; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Lilly; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Takeharu Yamanaka
Honoraria - Boehringer Ingelheim; Chugai Pharma; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Gilead Sciences
Research Funding - Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Tadamichi Denda
Research Funding - Boehringer Ingelheim (Inst); MSD (Inst); Sanofi (Inst)
 
Katsunori Shinozaki
Honoraria - Asahi Kasei; Chugai Pharma; Eisai; Hisamitsu Pharmaceutical; Kyowa Hakko Kirin; Lilly; Merck Serono; Mochida Pharmaceutical Co. Ltd.; MSD K.K; Novartis; Ono Pharmaceutical; Pfizer; Shionogi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Yoshito Komatsu
Honoraria - Bayer; Novartis; Pfizer
Speakers' Bureau - Bayer; Chugai Pharma; Lilly; Merck Serono; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - Bayer; Chugai Pharma; Lilly; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Pharmaceutical
 
Yoshimitsu Kobayashi
No Relationships to Disclose
 
Junji Furuse
Honoraria - Astellas Pharma; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Lilly Japan; Merck Serono; Mochida Pharmaceutical Co. Ltd.; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sawai Pharmaceutical Co; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Asahi Kasei; Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Kyowa Hakko Kirin; MSD; Novartis; Ono Pharmaceutical; Otsuka; Sandoz; Sanofi; Sawai Pharmaceutical Co; Shionogi; Shire; Sumitomo Dainippon; Taiho Pharmaceutical; Yakult Honsha; Zeria Pharmaceutical
Speakers' Bureau - Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Baxalta/Shire (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); J-Pharma (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst); Zeria Pharmaceutical (Inst)
 
Hiroyuki Okuda
No Relationships to Disclose
 
Masako Asayama
Research Funding - Takeda (Inst)
 
Kohei Akiyoshi
No Relationships to Disclose
 
Yoshinori Kagawa
No Relationships to Disclose
 
Takeshi Kato
Honoraria - Bayer; Chugai Pharma; Lilly; Sanofi; Takeda; Yakult Honsha
Research Funding - Chugai Pharma
 
Eiji Oki
Speakers' Bureau - Bayer Yakuhin; Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Takashi Ando
No Relationships to Disclose
 
Yasuhiro Hagiwara
Employment - EPS Holdings
 
Yasuo Ohashi
Leadership - EP-Cruse Co., Ltd; Statcom
Stock and Other Ownership Interests - Statcom
Honoraria - Chugai Pharma; Daiichi Sankyo; Kowa; Sanofi; Shionogi
Research Funding - Eisai (Inst); Yakult Pharmaceutical
Travel, Accommodations, Expenses - Yakult Pharmaceutical
 
Takayuki Yoshino
Honoraria - Chugai Pharma; Lilly Japan; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim (Inst); GlaxoSmithKline K.K. (Inst)